Vivek Subbiah Selected Research

Histone Deacetylase Inhibitors

11/2020	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
1/2020	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
10/2016	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Vivek Subbiah Research Topics

Disease

229	Neoplasms (Cancer) 04/2024 - 07/2007
30	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 07/2015
27	Sarcoma (Soft Tissue Sarcoma) 12/2023 - 03/2010
23	Disease Progression 12/2023 - 09/2008
19	Neoplasm Metastasis (Metastasis) 12/2023 - 04/2011
18	Melanoma (Melanoma, Malignant) 05/2023 - 01/2010
17	Thyroid Neoplasms (Thyroid Cancer) 03/2024 - 01/2017
12	Osteosarcoma (Osteogenic Sarcoma) 01/2022 - 07/2011
11	Diarrhea 02/2024 - 05/2012
11	Ewing Sarcoma (Sarcoma, Ewing) 01/2022 - 04/2009
10	medullary Thyroid cancer 11/2023 - 02/2015
9	Hypertension (High Blood Pressure) 02/2024 - 01/2017
9	Thrombocytopenia (Thrombopenia) 12/2023 - 06/2015
7	Fatigue 02/2024 - 11/2016
7	Nausea 02/2024 - 05/2012
7	Breast Neoplasms (Breast Cancer) 12/2023 - 01/2014
7	Anaplastic Thyroid Carcinoma 05/2023 - 08/2015
7	Cholangiocarcinoma 01/2023 - 01/2013
7	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 12/2014
7	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2014
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 12/2023 - 01/2020
6	Exanthema (Rash) 12/2023 - 01/2017
6	Lung Neoplasms (Lung Cancer) 01/2023 - 10/2019
5	Microsatellite Instability 01/2024 - 01/2019
5	Neutropenia 12/2023 - 06/2015
5	Carcinogenesis 10/2023 - 08/2019
5	Vomiting 10/2023 - 05/2012
5	Adenocarcinoma 04/2023 - 07/2015
5	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2023 - 03/2010
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 02/2015
5	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 11/2007
5	Desmoplastic Small Round Cell Tumor 10/2018 - 04/2011
4	Endometrial Neoplasms (Endometrial Cancer) 02/2024 - 10/2021
4	Leiomyosarcoma 12/2023 - 12/2016
4	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 08/2015
4	Carcinoma (Carcinomatosis) 01/2023 - 03/2020
4	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2023 - 01/2020
3	Mucositis 02/2024 - 01/2021
3	Pancreatic Neoplasms (Pancreatic Cancer) 09/2023 - 01/2021
3	Chondrosarcoma 01/2023 - 07/2011
3	Hairy Cell Leukemia 01/2023 - 08/2013
3	Glioma (Gliomas) 01/2023 - 12/2018

Drug/Important Bio-Agent (IBA)

19	selpercatinibIBA 03/2024 - 01/2020
18	Biomarkers (Surrogate Marker)IBA 03/2024 - 01/2014
18	Phosphotransferases (Kinase)IBA 01/2024 - 07/2011
18	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2023 - 01/2014
15	pralsetinibIBA 01/2024 - 01/2018
13	trametinibIBA 05/2023 - 01/2017
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 08/2014
12	VemurafenibIBA 02/2023 - 08/2015
12	pazopanib FDA Link 01/2023 - 06/2015
11	pembrolizumabIBA 01/2024 - 01/2019
11	Tyrosine Kinase InhibitorsIBA 01/2023 - 06/2015
9	vandetanib (ZD6474)IBA 11/2023 - 02/2015
9	Immune Checkpoint InhibitorsIBA 10/2023 - 12/2017
9	Everolimus FDA Link 02/2023 - 06/2015
9	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 06/2015
8	PM 01183IBA 12/2023 - 01/2020
8	dabrafenibIBA 05/2023 - 01/2018
8	TOR Serine-Threonine KinasesIBA 01/2018 - 08/2010
7	Bevacizumab (Avastin)FDA Link 12/2023 - 04/2016
7	CrizotinibIBA 02/2023 - 07/2011
7	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 01/2014
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2011
7	Cell-Free Nucleic AcidsIBA 01/2020 - 01/2016
6	PlatinumIBA 12/2023 - 08/2014
6	Circulating Tumor DNAIBA 12/2023 - 10/2019
6	Gemcitabine FDA Link 01/2023 - 01/2018
6	Radium-223IBA 01/2022 - 01/2014
5	cabozantinibIBA 11/2023 - 01/2020
5	Cetuximab (Erbitux)FDA Link 01/2020 - 08/2015
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 08/2014
4	CreatinineIBA 12/2023 - 04/2008
4	temsirolimus FDA Link 12/2023 - 01/2014
4	GenieIBA 11/2023 - 08/2019
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2023 - 04/2017
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2023 - 01/2020
4	Alanine Transaminase (SGPT)IBA 10/2023 - 01/2020
4	Paclitaxel (Taxol)FDA LinkGeneric 04/2023 - 01/2019
4	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2018
4	selinexorIBA 04/2022 - 01/2021
4	RadiopharmaceuticalsIBA 10/2021 - 01/2014
4	IpilimumabIBA 01/2021 - 01/2017
4	Vorinostat FDA Link 11/2020 - 10/2016
3	sapanisertibIBA 02/2024 - 04/2023
3	tyrosine receptor (receptor, tyrosine)IBA 01/2024 - 01/2022
3	Topotecan (Hycamtin)FDA LinkGeneric 12/2023 - 10/2021
3	LigandsIBA 10/2023 - 07/2011
3	Cadherins (E-Cadherin)IBA 09/2023 - 11/2020
3	Carboplatin (JM8)FDA LinkGeneric 04/2023 - 01/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2023 - 02/2022
3	ErbB Receptors (EGF Receptor)IBA 01/2023 - 01/2016

Therapy/Procedure

155	Therapeutics 04/2024 - 07/2007
40	Drug Therapy (Chemotherapy) 01/2024 - 11/2007
30	Immunotherapy 11/2023 - 12/2017
12	Precision Medicine 12/2023 - 03/2014
7	Radiotherapy 01/2023 - 05/2012
6	Investigational Therapies (Experimental Therapy) 02/2023 - 04/2009
4	Time-to-Treatment 10/2021 - 10/2016
3	Drug Tapering 11/2023 - 01/2018